<DOC>
	<DOCNO>NCT01116206</DOCNO>
	<brief_summary>The purpose study compare efficacy safety prucalopride placebo ( inactive substance compare drug test whether drug real effect clinical trial ) treatment participant chronic ( serious , life threaten ) constipation ( decreased number difficulty make bowel [ intestine ] movement ) .</brief_summary>
	<brief_title>An Efficacy Safety Study Prucalopride Participants With Chronic Constipation</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , double-blind ( neither physician participant know treatment participant receive ) , placebo-controlled , multi-center ( 1 hospital medical school team work medical research study ) study parallel-group design ( medical research study compare response 2 group participant receive different treatment ) study prucalopride . This study consist 3 phase : 2 week drug-free screen run phase , 12-week treatment phase follow-up ( post-treatment ) phase perform 7 day follow last dose study drug . The total duration study approximately 15 20 week , include run-in post-treatment phase . During run-in phase , participant receive laxative ( bisacodyl ) rescue medication throughout study , bowel movement ( BM ) 3 consecutive day . If participant able tolerate bisacodyl , enema may use place bisacodyl . During double-blind treatment phase , participant randomly assign 1:1 ratio 1 2 treatment group receive either 2 milligram ( mg ) prucalopride match placebo prucalopride 12 week , orally daily . Participants primarily assess spontaneous complete bowel movement ( SCBMs ) per week . Participant 's safety quality life monitor throughout study .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>History chronic constipation , defined average , 2 few spontaneous bowel movement ( SBMs ) per week 1 follow least quarter time last 3 month , symptom onset 6 month screen visit : 25 percent ( % ) BMs , participant hard ( little ball ) and/or hard stool , sensation incomplete evacuation , strain defecation ( make bowel movement ) , sensation anorectal obstruction blockade , and/or need digital manipulation facilitate evacuation Participants consider constipate ( never SBMs ) Participant 's constipation functional Participants diagnosis irritable bowel syndrome ( bowel disorder pain diarrhea constipation ) constipation organic disease potentially include depend decision investigator Female participant must postmenopausal ( least 1 year ) surgically sterile practice highly effective method birth control Secondary diseases/conditions ( endocrine disorder , metabolic disorder neurologic disorder druginduced suspected organic disorder large bowel , i.e. , obstruction , carcinoma ( type cancer ) , inflammatory bowel disease ) Participants Using intend use disallow medication may influence bowel habit study Participants severe ( serious , life threaten ) clinically uncontrolled cardiovascular , liver , lung disease , neurologic psychiatric disorder ( include active alcohol drug abuse ) , cancer ( abnormal tissue grow spread body kill ) acquire immune deficiency syndrome ( AIDS : illness result decrease ability body protect illness ; development disease condition associate disease result Human Immunodeficiency Virus [ HIV ] ) , gastrointestinal endocrine disorder Participants impair renal function , , serum creatinine great 2 milligram per deciliter ( great 180 micro mole per liter ) Participants clinically significant abnormality hematology , urinalysis , blood chemistry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Constipation</keyword>
	<keyword>Prucalopride</keyword>
	<keyword>Resolor</keyword>
</DOC>